261 related articles for article (PubMed ID: 8204875)
1. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.
Bührer C; Hartmann R; Fengler R; Schober S; Arlt I; Loewke M; Henze G
Blood; 1994 Jun; 83(12):3468-72. PubMed ID: 8204875
[TBL] [Abstract][Full Text] [Related]
2. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
3. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
4. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.
Henze G; Fengler R; Hartmann R; Kornhuber B; Janka-Schaub G; Niethammer D; Riehm H
Blood; 1991 Sep; 78(5):1166-72. PubMed ID: 1878583
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
[TBL] [Abstract][Full Text] [Related]
8. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G
J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343
[TBL] [Abstract][Full Text] [Related]
10. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
[TBL] [Abstract][Full Text] [Related]
11. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
12. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
J Clin Oncol; 1993 Mar; 11(3):520-6. PubMed ID: 8445427
[TBL] [Abstract][Full Text] [Related]
13. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
Reiter A; Schrappe M; Ludwig WD; Lampert F; Harbott J; Henze G; Niemeyer CM; Gadner H; Müller-Weihrich S; Ritter J
Blood; 1992 Nov; 80(10):2471-8. PubMed ID: 1421370
[TBL] [Abstract][Full Text] [Related]
14. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
Stark B; Sharon R; Rechavi G; Attias D; Ballin A; Cividalli G; Burstein Y; Sthoeger D; Abramov A; Zaizov R
Cancer; 2000 Jan; 88(1):205-16. PubMed ID: 10618625
[TBL] [Abstract][Full Text] [Related]
15. Therapy of B-cell acute lymphoblastic leukaemia in childhood: the BFM experience.
Reiter A
Baillieres Clin Haematol; 1994 Jun; 7(2):321-37. PubMed ID: 7803904
[TBL] [Abstract][Full Text] [Related]
16. High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.
von Stackelberg A; Hartmann R; Bührer C; Fengler R; Janka-Schaub G; Reiter A; Mann G; Schmiegelow K; Ratei R; Klingebiel T; Ritter J; Henze G;
Blood; 2008 Mar; 111(5):2573-80. PubMed ID: 18089849
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials.
Bührer C; Henze G; Hofmann J; Reiter A; Schellong G; Riehm H
Haematol Blood Transfus; 1990; 33():500-3. PubMed ID: 2182444
[TBL] [Abstract][Full Text] [Related]
18. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
[TBL] [Abstract][Full Text] [Related]
19. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report.
Laver JH; Barredo JC; Amylon M; Schwenn M; Kurtzberg J; Camitta BM; Pullen J; Link MP; Borowitz M; Ravindranath Y; Murphy SB; Shuster J
Leukemia; 2000 Mar; 14(3):369-73. PubMed ID: 10720128
[TBL] [Abstract][Full Text] [Related]
20. Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia.
Bührer C; Hartmann R; Fengler R; Dopfer R; Gadner H; Gerein V; Göbel U; Reiter A; Ritter J; Henze G
Med Pediatr Oncol; 1993; 21(7):470-6. PubMed ID: 8341213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
